- Home
- OBIO vs NERV Comparison
OBIO vs NERV Comparison
Compare OBIO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | NERV |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 269.6M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OBIO | NERV |
|---|---|---|
| Price | $4.37 | $6.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $14.25 | $4.00 |
| AVG Volume (30 Days) | ★ 206.0K | 103.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 104.12 |
| EPS | N/A | ★ N/A |
| Revenue | $2,638,000.00 | ★ $41,175,600.00 |
| Revenue This Year | $36.66 | N/A |
| Revenue Next Year | $2.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.20 | $1.15 |
| 52 Week High | $5.42 | $12.46 |
Technical Indicators
Market Signals| Indicator | OBIO | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 71.88 |
| Support Level | $4.00 | $5.66 |
| Resistance Level | $5.00 | $6.69 |
| Average True Range (ATR) | 0.26 | 0.56 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 90.00 | 93.69 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.